In a study of 1,125 patients from 30 countries, researchers looked at adding cetuximab (Erbitux) to chemotherapy with cisplatin (Platinol) and vinorelbine (Navelbine) for patients newly diagnosed with advanced non-small cell lung cancer (NSCLC).
Canadian researchers performed a genetic analysis of frozen, banked tumor samples from 133 patients with early-stage non-small cell lung cancer (NSCLC) to identify a set of genes that could predict whether a patient would benefit from adjuvant chemotherapy (treatment after surgery).
Researchers looked at the effect of maintenance therapy with pemetrexed (Alimta) given 3 to 6 weeks after completing a first treatment with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC).
Adding shark cartilage extract to standard chemotherapy and radiation therapy for patients with advanced non-small cell lung cancer does not extend patients' lives, according to a large phase III clinical trial.
A report from Dutch researchers shows that giving radiation therapy to the head lowers the risk of the spread of cancer to the brain and helps patients with extensive-stage small cell lung cancer live longer.
A new survey of primary care doctors in Wisconsin shows they are less likely to refer patients with advanced lung cancer to an oncologist than they are to refer patients with advanced breast cancer. This difference was seen despite the fact that most doctors surveyed said that the type and stage of a patient's cancer did not influence how strongly they encouraged patients to seek treatment.
Results of a new study show that adding bevacizumab (Avastin) to chemotherapy helps people with non-small cell lung cancer (NSCLC) live longer. Bevacizumab stops angiogenesis, the process of forming new blood vessels, which helps tumors grow and spread.
A new study shows that paclitaxel (Taxol) is more effective but also more toxic in Japanese patients with advanced stage non-small cell lung cancer (NSCLC) than in U.S. patients. Non-small cell lung cancer is the most common type of lung cancer.
A new study shows that giving chemotherapy after surgery (adjuvant chemotherapy) results in a significant survival advantage in people with stage IB non-small cell lung cancer (NSCLC). Stage IB NSCLC describes a small to medium-sized tumor that has not spread to the lymph nodes. This type of lung cancer is currently treated with surgery. The purpose of this study was to learn whether chemotherapy after surgery helped people with stage IB NSCLC live longer, because the results of previous studies have been conflicting.
A new study finds an increased risk of severe digestive side effects in patients with a specific genetic variation who were treated with radiation and platinum-based chemotherapy for non-small cell lung cancer (NSCLC).
